0000000000304029

AUTHOR

Danilo Toni

showing 5 related works from this author

Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagon…

2022

Background: In patients with atrial fibrillation who suffered an ischemic stroke while on treatment with nonvitamin K antagonist oral anticoagulants, rates and determinants of recurrent ischemic events and major bleedings remain uncertain. Methods: This prospective multicenter observational study aimed to estimate the rates of ischemic and bleeding events and their determinants in the follow-up of consecutive patients with atrial fibrillation who suffered an acute cerebrovascular ischemic event while on nonvitamin K antagonist oral anticoagulant treatment. Afterwards, we compared the estimated risks of ischemic and bleeding events between the patients in whom anticoagulant therapy was chan…

OralAdvanced and Specialized NursinghypertensionrecurrenceanticoagulantAdministration OralAnticoagulantsHemorrhageSettore MED/26Brain IschemiaStrokeRisk FactorsAdministrationAtrial FibrillationHumansSettore MED/26 - NeurologiaHuman medicineNeurology (clinical)Prospective StudiesCardiology and Cardiovascular MedicineAnticoagulants; atrial fibrillation; hypertension; ischemic stroke; recurrenceIschemic StrokeStroke
researchProduct

Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy.

2021

Summary Background Among asymptomatic patients with severe carotid artery stenosis but no recent stroke or transient cerebral ischaemia, either carotid artery stenting (CAS) or carotid endarterectomy (CEA) can restore patency and reduce long-term stroke risks. However, from recent national registry data, each option causes about 1% procedural risk of disabling stroke or death. Comparison of their long-term protective effects requires large-scale randomised evidence. Methods ACST-2 is an international multicentre randomised trial of CAS versus CEA among asymptomatic patients with severe stenosis thought to require intervention, interpreted with all other relevant trials. Patients were eligib…

Malemedicine.medical_specialtyTime FactorsTime Factormedicine.medical_treatmentCarotid StenosiMEDLINECarotid endarterectomyRate ratioRisk AssessmentAsymptomaticlaw.inventionRandomized controlled triallawRisk Factorscarotid artery stenting (CAS); carotid endarterectomy (CEA)StentmedicineHumansCarotid StenosisStrokeEndarterectomyAgedEndarterectomy Carotidbusiness.industrycarotid arteryRisk FactorArticlesGeneral Medicinetrialmedicine.diseaseSettore MED/22 - CHIRURGIA VASCOLARESurgeryStrokeStenosisTreatment Outcomecarotid artery stenting (CAS)Settore MED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREFemaleStentsHuman medicinemedicine.symptomcarotid endarterectomy (CEA)businessHumanLancet (London, England)
researchProduct

Reduced Admissions for Cerebrovascular Events during COVID-19 Outbreak in Italy

2020

Supplemental Digital Content is available in the text.

disease outbreakMalemedicine.medical_treatment030204 cardiovascular system & hematologyItaly; cerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient0302 clinical medicineEpidemiology80 and overMedicineischemic attack transientThrombolytic Therapy10178Acute ischemic stroke10177ThrombectomyAged 80 and overIschemic AttackTransientIncidence (epidemiology)Endovascular ProceduresMiddle AgedHospitalization1006210183ItalyComputingMethodologies_DOCUMENTANDTEXTPROCESSINGSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinecerebral hemorrhage; disease outbreaks; incidence; ischemic attack transient; Italy; Aged; Aged 80 and over; COVID-19; Cerebral Hemorrhage; Endovascular Procedures; Female; Hospitalization; Humans; Ischemic Attack Transient; Ischemic Stroke; Italy; Male; Middle Aged; Thrombectomy; Thrombolytic Therapymedicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)RevascularizationSettore MED/261015203 medical and health sciencesHumansAgedIschemic StrokeAdvanced and Specialized Nursingcerebral hemorrhagebusiness.industryOutbreakCOVID-19Emergency medicinedisease outbreaksincidenceBrief ReportsNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Primary stroke prevention worldwide:translating evidence into action

2021

Abstract: Stroke is the second leading cause of death and the third leading cause of disability worldwide and its burden is increasing rapidly in low-income and middle-income countries, many of which are unable to face the challenges it imposes. In this Health Policy paper on primary stroke prevention, we provide an overview of the current situation regarding primary prevention services, estimate the cost of stroke and stroke prevention, and identify deficiencies in existing guidelines and gaps in primary prevention. We also offer a set of pragmatic solutions for implementation of primary stroke prevention, with an emphasis on the role of governments and population-wide strategies, includin…

Global Burden of Disease03 medical and health sciences0302 clinical medicineNursingBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Neurology.Medicine030212 general & internal medicineStrokeHealth policyCause of deathEntire populationHealth professionalsbusiness.industryHealth PolicyPublic Health Environmental and Occupational HealthBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Neurologija.medicine.disease3. Good healthStrokeAction (philosophy)Stroke preventionOcclusive Cerebrovascular DiseaseLife course approachHuman medicinebusiness030217 neurology & neurosurgery
researchProduct

Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention

2021

Background and Purpose: Clinical trials on stroke prevention in patients with atrial fibrillation have consistently shown clinical benefit from either warfarin or non–vitamin K antagonist oral anticoagulants (NOACs). NOAC-treated patients have consistently reported to be at lower risk for intracerebral hemorrhage (ICH) than warfarin-treated patients. The aims of this prospective, multicenter, multinational, unmatched, case-control study were (1) to investigate for risk factors that could predict ICH occurring in patients with atrial fibrillation during NOAC treatment and (2) to evaluate the role of CHA 2 DS 2 -VASc and HAS-BLED scores in the same setting. Methods: Cases were consecutive pa…

MaleAdministration Oral030204 cardiovascular system & hematologySettore MED/110302 clinical medicine80 and overrisk factorsMedicineatrial fibrillationProspective StudiesAged 80 and overatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matter; Administration Oral; Aged; Aged 80 and over; Antithrombins; Atrial Fibrillation; Case-Control Studies; Cerebral Hemorrhage; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; StrokeAtrial fibrillationMiddle AgedVitamin K antagonist3. Good healthStrokeAdministrationSettore MED/26 - NeurologiaFemaleCardiology and Cardiovascular Medicinewhite mattermedicine.drugOralmedicine.medical_specialtymedicine.drug_classSettore MED/26Lower riskAntithrombins03 medical and health sciencesInternal medicineHumanscardiovascular diseaseslogistic modelAgedAdvanced and Specialized NursingIntracerebral hemorrhagecerebral hemorrhagebusiness.industryWarfarinmedicine.diseaseClinical trialatrial fibrillation; cerebral hemorrhage; logistic models; risk factors; white matterCase-Control StudiesConcomitantHeart failureNeurology (clinical)businesslogistic models030217 neurology & neurosurgeryStroke
researchProduct